ARQT Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arcutis Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.30 |
| 52 Week High | US$15.79 |
| 52 Week Low | US$3.07 |
| Beta | 1.32 |
| 1 Month Change | 9.66% |
| 3 Month Change | 49.74% |
| 1 Year Change | 342.72% |
| 3 Year Change | -37.25% |
| 5 Year Change | n/a |
| Change since IPO | -34.40% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump
Nov 27
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Shareholder Returns
| ARQT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | 0.7% | 0.6% |
| 1Y | 342.7% | -3.4% | 23.7% |
Return vs Industry: ARQT exceeded the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: ARQT exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| ARQT volatility | |
|---|---|
| ARQT Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARQT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARQT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 296 | Frank Watanabe | www.arcutis.com |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.
Arcutis Biotherapeutics, Inc. Fundamentals Summary
| ARQT fundamental statistics | |
|---|---|
| Market cap | US$1.67b |
| Earnings (TTM) | -US$195.53m |
| Revenue (TTM) | US$138.71m |
12.1x
P/S Ratio-8.6x
P/E RatioIs ARQT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARQT income statement (TTM) | |
|---|---|
| Revenue | US$138.71m |
| Cost of Revenue | US$14.47m |
| Gross Profit | US$124.24m |
| Other Expenses | US$319.77m |
| Earnings | -US$195.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 89.57% |
| Net Profit Margin | -140.97% |
| Debt/Equity Ratio | 130.6% |
How did ARQT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 20:44 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcutis Biotherapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Chris Shibutani | Goldman Sachs |
| Seamus Fernandez | Guggenheim Securities, LLC |